{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.8","upperLimit":"81.3","value":"71.0"},{"groupId":"OG001","lowerLimit":"38.7","upperLimit":"70.2","value":"54.8"},{"groupId":"OG002","lowerLimit":"32.6","upperLimit":"60.4","value":"46.3"},{"groupId":"OG003","lowerLimit":"34.3","upperLimit":"71.7","value":"53.3"},{"groupId":"OG004","lowerLimit":"66.7","upperLimit":"87.3","value":"78.3"},{"groupId":"OG005","lowerLimit":"38.4","upperLimit":"88.2","value":"66.7"},{"groupId":"OG006","lowerLimit":"81.7","upperLimit":"99.9","value":"96.4"},{"groupId":"OG007","lowerLimit":"29.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG008","lowerLimit":"74.2","upperLimit":"98.0","value":"90.3"},{"groupId":"OG009","lowerLimit":"89.1","upperLimit":"100.0","value":"100.0"},{"groupId":"OG010","lowerLimit":"73.1","upperLimit":"89.0","value":"82.0"},{"groupId":"OG011","lowerLimit":"91.1","upperLimit":"100.0","value":"98.3"}]}],"title":"By BIRC assessment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.4","upperLimit":"72.4","value":"60.9"},{"groupId":"OG001","lowerLimit":"29.8","upperLimit":"61.3","value":"45.2"},{"groupId":"OG002","lowerLimit":"30.9","upperLimit":"58.6","value":"44.4"},{"groupId":"OG003","lowerLimit":"28.3","upperLimit":"65.7","value":"46.7"},{"groupId":"OG004","lowerLimit":"65.1","upperLimit":"86.1","value":"76.8"},{"groupId":"OG005","lowerLimit":"44.9","upperLimit":"92.2","value":"73.3"},{"groupId":"OG006","lowerLimit":"81.7","upperLimit":"99.9","value":"96.4"},{"groupId":"OG007","lowerLimit":"29.2","upperLimit":"100.0","value":"100.0"},{"groupId":"OG008","lowerLimit":"74.2","upperLimit":"98.0","value":"90.3"},{"groupId":"OG009","lowerLimit":"83.8","upperLimit":"99.9","value":"96.9"},{"groupId":"OG010","lowerLimit":"71.9","upperLimit":"88.2","value":"81.0"},{"groupId":"OG011","lowerLimit":"88.5","upperLimit":"99.6","value":"96.7"}]}],"title":"By investigator assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"}],"units":"Participants"}],"description":"Percentage of participants with a best overall response of confirmed CR, PR or stable disease (SD) per RECIST 1.1 by BIRC and investigator assessment.\n\nCR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.\n\nSD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"}],"paramType":"NUMBER","populationDescription":"FAS, including all subjects who received at least one dose of capmatinib.","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}